Citadel Advisors’s Neos Therapeutics, Inc NEOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-10,705
| Closed | -$6.61K | – | 11809 |
|
|
2020
Q3 | $6K | Buy |
+10,705
| New | +$7.28K | ﹤0.01% | 9960 |
|
|
2020
Q2 | – | Sell |
-34,271
| Closed | -$26K | – | 10819 |
|
|
2020
Q1 | $26K | Buy |
+34,271
| New | +$47.1K | ﹤0.01% | 9240 |
|
|
2019
Q3 | – | Sell |
-15,845
| Closed | -$20K | – | 10030 |
|
|
2019
Q2 | $20K | Sell |
15,845
-42,267
| -73% | -$77.8K | ﹤0.01% | 8951 |
|
|
2019
Q1 | $152K | Buy |
58,112
+29,878
| +106% | +$70.1K | ﹤0.01% | 8381 |
|
|
2018
Q4 | $47K | Sell |
28,234
-27,972
| -50% | -$78.5K | ﹤0.01% | 8505 |
|
|
2018
Q3 | $273K | Buy |
56,206
+28,908
| +106% | +$164K | ﹤0.01% | 7732 |
|
|
2018
Q2 | $171K | Buy |
+27,298
| New | +$204K | ﹤0.01% | 8000 |
|
|
2018
Q1 | – | Sell |
-10,730
| Closed | -$109K | – | 9013 |
|
|
2017
Q4 | $109K | Sell |
10,730
-56,712
| -84% | -$544K | ﹤0.01% | 7401 |
|
|
2017
Q3 | $617K | Buy |
+67,442
| New | +$513K | ﹤0.01% | 5010 |
|
|
2016
Q1 | – | Sell |
-26,087
| Closed | -$374K | – | 8464 |
|
|
2015
Q4 | $374K | Buy |
+26,087
| New | +$393K | ﹤0.01% | 4883 |
|
Citadel Advisors's NEOS Position: Q4 2020 in Review
Citadel Advisors sold out of Neos Therapeutics, Inc (NEOS) in Q4 2020, closing a stake of 10,705 shares — an estimated $6.61K sold.
Citadel Advisors first reported a position in NEOS in Q4 2015 and held it in 10 quarters. The position peaked at $617K in Q3 2017. 37 funds tracked by Wall St. Rank hold NEOS as of Q4 2020.
- Citadel Advisors reported no remaining Neos Therapeutics, Inc position as of Q4 2020 after selling out during the quarter.
- Citadel Advisors sold 10,705 Neos Therapeutics, Inc shares in Q4 2020, an estimated $6.61K.
- Citadel Advisors first reported a position in Neos Therapeutics, Inc in Q4 2015 and held it in 10 quarters.
- Citadel Advisors's Neos Therapeutics, Inc position peaked at $617K in Q3 2017.
- 37 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q4 2020.
Based on Citadel Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.